Press Releases | Investor Relations | Eledon Pharmaceuticals, Inc.

05/09/2024	Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
05/09/2024	Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
05/07/2024	Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
05/07/2024	Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
03/28/2024	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
03/25/2024	Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
03/21/2024	Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
02/13/2024	Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/04/2024	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook